Skip to main content

Table 4 Patients responding to treatment as assessed by serum β-CTx reduction at 26 weeks

From: Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

Percent Reduction of β-CTx

Group I (N = 28)

Group II (N = 64)

Group III (N = 94)

Total (N = 186)

≥ 30%, n (%)

12 (42.9)

44 (68.7)

91 (96.8)

147 (79.0)

≥ 50%, n (%)

7 (25.0)

37 (57.8)

89 (94.7)

133 (71.5)

  1. Group I: Recent/current bisphosphonate-, strontium-, estrogen-, or SERM-treated patients; Group II: Patients being treated with other drugs; Group III: Treatment-naïve patients. β-CTx Beta-CrossLaps, SERM selective receptor estrogen modulator